Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier

Developments of a water-maze procedure for studying spatial learning in the rat

Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180 · see citing works

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works

β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE

Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1× · see citing works

Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension: Final Results of the Systolic Hypertension in the Elderly Program (SHEP)

(1991) · JAMA · doi:10.1001/jama.1991.03460240051027 · Cited by 2,953 · see citing works

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · see citing works

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial

Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · see citing works

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426 · see citing works

Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier

Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · see citing works

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · see citing works

Alzheimer's disease: strategies for disease modification

Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works

Evidence that production and release of amyloid beta-protein involves the endocytic pathway

Koo, E. H., & Squazzo, S. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32449-3 · Cited by 989 · see citing works

The Prevention of Dementia With Antihypertensive Treatment<subtitle>New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study</subtitle>

Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · see citing works

Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition

Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · see citing works

Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease

Bell, R. D., & Zloković, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 855 · see citing works

LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms

Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828 · see citing works

Neuropathology of Alzheimer's Disease

Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825 · see citing works

An overview of APP processing enzymes and products.

Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8104-z · Cited by 684 · see citing works

Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · see citing works

Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease

Deane, R., Bell, R. D., Sagare, A. P., & Zloković, B. V. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 549 · see citing works

The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells

Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H., Yamamoto, Y., & Yamamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001235200 · Cited by 425 · see citing works

Clearance of amyloid β-peptide from brain: transport or metabolism?

Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., & Frangione, B. (2000) · Nature Medicine · doi:10.1038/77397 · Cited by 186 · see citing works

Gene structure and organization of the human β‐secretase ( BACE ) promoter

Sambamurti, K., Kinsey, R., Maloney, B., Ge, Y., & Lahiri, D. K. (2004) · The FASEB Journal · doi:10.1096/fj.03-1378fje · Cited by 179 · see citing works

Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease

Paris, D., Ganey, N. J., Laporte, V., Patel, N. S., Beaulieu‐Abdelahad, D., Bachmeier, C. J., March, A., Ait‐Ghezala, G., & MULLAN, M. J. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-17 · Cited by 169 · see citing works

AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation

Guglielmotto, M., Aragno, M., Tamagno, E., Vercellinatto, I., Visentin, S., Medana, C., Catalano, M. G., Smith, M. A., Perry, G. L., Danni, O., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.026 · Cited by 162 · see citing works

ApoE Deficiency Compromises the Blood Brain Barrier Especially After Injury

Methia, N., André, P., Hafezi-Moghadam, A., Economopoulos, M., Thomas, K. L., & Wagner, D. D. (2001) · Molecular Medicine · doi:10.1007/bf03401973 · Cited by 150 · see citing works

Thiazolidinediones Reduce Endothelial Expression of Receptors for Advanced Glycation End Products

Marx, N., Walcher, D., Ivanova, N., Rautzenberg, K., Jung, A., Friedl, R., Hombach, V., Caterina, R. D., Basta, G., Wautier, M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.10.2662 · Cited by 137 · see citing works

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

Fournier, A. E., Oprisiu, R., Sérot, J., Godefroy, O., Achard, J., Faure, S., Mazouz, H., Temmar, M., Albu, A., Bordet, R., et al. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.89 · Cited by 129 · see citing works

NFκB-dependent Control of BACE1 Promoter Transactivation by Aβ42

Buggia-Prévot, V., Sévalle, J., Roßner, S., & Checler, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706579200 · Cited by 125 · see citing works

VEGF Promotes Malaria-Associated Acute Lung Injury in Mice

Epiphânio, S., Campos, M. G., Pamplona, A., Carapau, D., Pena, A. C., Ataíde, R., Monteiro, C. A. A., Félix, N., Costa-Silva, A., Marinho, C. R. F., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000916 · Cited by 123 · see citing works

Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging

Yasar, S., Corrada, M., Brookmeyer, R., & Kawas, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.009 · Cited by 116 · see citing works

Amyloid‐β Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease

Lublin, A. L., & Gandy, S. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20160 · Cited by 116 · see citing works

Selectivities of Dihydropyridine Derivatives in Blocking Ca2+ Channel Subtypes Expressed in Xenopus Oocytes

Furukawa, T., Yamakawa, T., Midera, T., Sagawa, T., Mori, Y., & Nukada, T. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35127-4 · Cited by 116 · see citing works

Substitution at codon 22 reduces clearance of Alzheimer's amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood

Monro, O. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00317-7 · Cited by 107 · see citing works

Inhibitor of NF-κB Kinases α and β Are Both Essential for High Mobility Group Box 1-Mediated Chemotaxis

Penzo, M., Molteni, R., Suda, T., Samaniego, S., Raucci, A., Habiel, D. M., Miller, F. W., Jiang, H.-P., Li, J., Pardi, R., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903131 · Cited by 101 · see citing works

Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging.

Maxwell, C. J., Hogan, D. B., & Ebly, E. M. (1999) · PubMed · Cited by 101 · see citing works

Permeability of the blood-cerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone

Zloković, B. V., Segal, M. B., Begley, D. J., Davson, H., & Rakić, L. (1985) · Brain Research · doi:10.1016/0006-8993(85)90963-1 · Cited by 92 · see citing works

Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type.

Bellew, K. M., Pigeon, J. G., Stang, P., Fleischman, W. M., Gardner, R. M., & Baker, W. W. (2004) · PubMed · Cited by 91 · see citing works

Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes

Janus, C., D’Amelio, S., Amitay, O. A., Chishti, M. A., Strome, R., Fraser, P., Carlson, G. A., Roder, J., George‐Hyslop, P. S., & Westaway, D. A. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00107-x · Cited by 88 · see citing works

Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon

Mann, G. E., Zlokovic, B. V., & Yudilevich, D. L. (1985) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(85)90179-8 · Cited by 84 · see citing works

Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists

Uchida, S., Yamada, S., Nagai, K., Deguchi, Y., & Kimura, R. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00881-3 · Cited by 83 · see citing works

Antihypertensive Treatments, Cognitive Decline, and Dementia

Duron, E., & Hanon, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091552 · Cited by 81 · see citing works

Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice

Paris, D., Quadros, A., Humphrey, J., Patel, N. S., Crescentini, R. M., Crawford, F., & MULLAN, M. J. (2004) · Brain Research · doi:10.1016/j.brainres.2003.11.061 · Cited by 75 · see citing works

Inhibition of Aβ production by NF-κB inhibitors

Paris, D., Patel, N., Quadros, A., Linan, M., Bakshi, P., Ait-Ghezala, G., & Mullan, M. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.12.029 · Cited by 75 · see citing works

Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints

Hanon, O., Péquignot, R., Seux, M. L., Lenoir, H., Bune, A. J. C., Rigaud, A.-S., Forette, F., & Girerd, X. J. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000244961.69985.05 · Cited by 75 · see citing works

Effect of Surface Charge of Immortalized Mouse Cerebral Endothelial Cell Monolayer on Transport of Charged Solutes

Yuan, W., Li, G., & Fu, B. M. (2010) · Annals of Biomedical Engineering · doi:10.1007/s10439-010-9920-x · Cited by 68 · see citing works

Expression of Nitric Oxide Synthases and Nitrotyrosine during Blood-Brain Barrier Breakdown and Repair after Cold Injury

Nag, S., Picard, P., & Stewart, D. J. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780210 · Cited by 67 · see citing works

Prevention of dementia: lessons from SYST-EUR and PROGRESS

Hanon, O., & Forette, F. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.015 · Cited by 54 · see citing works

Nilvadipine prevents cognitive decline of patients with mild cognitive impairment

Hanyu, H., Hirao, K., Shimizu, S., Sato, T., Kiuchi, A., & Iwamoto, T. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1851 · Cited by 48 · see citing works

Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier

Bachmeier, C. J., MULLAN, M. J., & Paris, D. (2010) · Cytotechnology · doi:10.1007/s10616-010-9313-x · Cited by 34 · see citing works

Nilvadipine Prevents the Impairment of Spatial Memory Induced by Cerebral Ischemia Combined with .BETA.-Amyloid in Rats

Iwasaki, K., Egashira, N., Takagaki, Y., Yoshimitsu, Y., Hatip‐Al‐Khatib, I., Mishima, K., & Fujiwara, M. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.698 · Cited by 29 · see citing works

Alzheimer’s Disease and Neuronal Network Activity

Gleichmann, M., & Mattson, M. P. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8100-3 · Cited by 28 · see citing works

Nilvadipine inhibits nuclear factor-κB-dependent transcription in hepatic cells

Iwasaki, Y., Asai, M., Yoshida, M., Nigawara, T., Kambayashi, M., Oiso, Y., & Nakashima, N. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.07.012 · Cited by 13 · see citing works

Effect of Nilvadipine on Regional Cerebral Blood Flow in a Patient With Early Alzheimer Disease

Matsuda, H., Araki, N., Kuji, I., Ohkubo, T., Imabayashi, E., & Shimazu, K. (2008) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31815c4ff0 · Cited by 10 · see citing works

Effects of Nilvadipine on Cytokine-Levels and Soluble Factors in Collagen Disease Complicated with Essential Hypertension

Kagawa, H., Nomura, S., Ozaki, Y., Nagahama, M., & Fukuhara, S. (1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909052196 · Cited by 8 · see citing works

A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR γ agonists

Sato, T., Hanyu, H., Akai, T., Takasaki, A., Sakurai, H., & Iwamoto, T. (2008) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.45.428 · Cited by 6 · see citing works

Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study

Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · see citing works

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870 · see citing works

Clinical trials of new drugs for Alzheimer disease

Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · see citing works

Drug candidates in clinical trials for Alzheimer’s disease

Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420 · see citing works

Hypertension: A Harbinger of Stroke and Dementia

Faraco, G., & Iadecola, C. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01063 · Cited by 367 · see citing works

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 322 · see citing works

Drug repositioning for Alzheimer's disease

Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 302 · see citing works

Drug repositioning: Progress and challenges in drug discovery for various diseases

Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232 · see citing works

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193 · see citing works

The Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease

Stakos, D. A., Stamatelopoulos, K., Bampatsias, D., Sachse, M., Zormpas, E., Vlachogiannis, N. I., Tual-Chalot, S., & Stellos, K. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.033 · Cited by 188 · see citing works

Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier

Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184 · see citing works

Calcium channel blockers and dementia

Nimmrich, V., & Eckert, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12240 · Cited by 155 · see citing works

Is Alzheimer’s Disease Risk Modifiable?

Serrano‐Pozo, A., & Growdon, J. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad181028 · Cited by 157 · see citing works

Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease

Sahoo, A. K., Dandapat, J., Dash, U. C., & Kanhar, S. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.12.015 · Cited by 147 · see citing works

A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery

Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140 · see citing works

Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine

Anekonda, T. S., & Quinn, J. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.013 · Cited by 136 · see citing works

Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease

Александровна, П. Е., Pchitskaya, E. I., & Борисович, Б. И. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7506 · Cited by 102 · see citing works

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

Dunkel, P., Chai, C. L. L., Sperlágh, B., Huleatt, P. B., & Mátyus, P. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703178 · Cited by 103 · see citing works

Does Treating Vascular Risk Factors Prevent Dementia and Alzheimer’s Disease? A Systematic Review and Meta-Analysis

Larsson, S. C., & Markus, H. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180288 · Cited by 94 · see citing works

A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents

Appleby, B. S., Nacopoulos, D. A., Milano, N. J., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90 · see citing works

Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases

Pierzynowska, K., Gaffke, L., Cyske, Z., Puchalski, M., Rintz, E., Bartkowski, M., Osiadły, M., Pierzynowski, M., Mantej, J., Piotrowska, E., et al. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0214-6 · Cited by 89 · see citing works

Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease

Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 82 · see citing works

Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications

Appleby, B. S., & Cummings, J. L. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660162 · Cited by 78 · see citing works

The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation

Paris, D., Ait-Ghezala, G., Bachmeier, C., Laco, G., Beaulieu-Abdelahad, D., Lin, Y., Jin, C., Crawford, F., & Mullan, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608091 · Cited by 73 · see citing works

β-Secretase: its biology as a therapeutic target in diseases

Wang, H., Li, R., & Shen, Y. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.008 · Cited by 74 · see citing works

L-type Ca2+ currents at CA1 synapses, but not CA3 or dentate granule neuron synapses, are increased in 3xTgAD mice in an age-dependent manner

Wang, Y., & Mattson, M. P. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.007 · Cited by 72 · see citing works

Protective effects of low molecular weight chondroitin sulfate on amyloid beta (Aβ)-induced damage in vitro and in vivo

Zhang, Q., Li, J., Liu, C., Song, C., Li, P., Yin, F., Xiao, Y., Li, J., Jiang, W., Zong, A., et al. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.002 · Cited by 66 · see citing works

In Vitro Screening for Drug Repositioning

WILKINSON, G. F., & Pritchard, K. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114563024 · Cited by 66 · see citing works

Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing

Uddin, M. S., Kabir, M. T., Jeandet, P., Mathew, B., Ashraf, G. M., Perveen, A., Bin-Jumah, M. N., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7039138 · Cited by 65 · see citing works

A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease

Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64 · see citing works

Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer’s Disease

Dubey, S. K., Munnangi, S. R., Krishna, K. V., Saha, R. N., Singhvi, G., Agrawal, M., Ajazuddin, M., Saraf, S., Saraf, S., & Alexander, A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00653-z · Cited by 62 · see citing works

Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier

Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.048 · Cited by 61 · see citing works

Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex

Ashby, E. L., Miners, J. S., Kehoe, P. G., & Love, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150831 · Cited by 56 · see citing works

A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly

Peters, R. K., Booth, A., & Peters, J. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000273 · Cited by 57 · see citing works

Antihypertensive agents in Alzheimer’s disease: beyond vascular protection

Lebouvier, T., Chen, Y. S., Duriez, P., Pasquier, F., & Bordet, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1708195 · Cited by 55 · see citing works

Role of the cannabinoid system in the transit of beta-amyloid across the blood–brain barrier

Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.06.004 · Cited by 55 · see citing works

Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: a meta-analysis of prospective studies

Hussain, S., Singh, A., Rahman, S. O., Habib, A., & Najmi, A. K. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.02.027 · Cited by 52 · see citing works

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Corbett, A., Williams, G. H., & Ballard, C. G. (2013) · Pharmaceuticals · doi:10.3390/ph6101304 · Cited by 50 · see citing works

Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing

Bachmeier, C. J., Shackleton, B., Ojo, J. O., Paris, D., MULLAN, M. J., & Crawford, F. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8318-6 · Cited by 50 · see citing works

New Evidence for P-gp-Mediated Export of Amyloid-β Peptides in Molecular, Blood-Brain Barrier and Neuronal Models

Chai, A. B., Hartz, A. M. S., Gao, X., Yang, A., Callaghan, R., & Gelissen, I. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010246 · Cited by 50 · see citing works

The association between hypertensive arteriopathy and cerebral amyloid angiopathy in spontaneously hypertensive stroke‐prone rats

Jandke, S., Garz, C., Schwanke, D., Sendtner, M., Heinze, H., Carare, R. O., & Schreiber, S. (2018) · Brain Pathology · doi:10.1111/bpa.12629 · Cited by 46 · see citing works

A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier

Bachmeier, C. J., Paris, D., Beaulieu‐Abdelahad, D., Mouzon, B., MULLAN, M. J., & Crawford, F. (2012) · Neurodegenerative Diseases · doi:10.1159/000337231 · Cited by 48 · see citing works

Targeting microglia L‐type voltage‐dependent calcium channels for the treatment of central nervous system disorders

Hopp, S. C. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24585 · Cited by 48 · see citing works

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease

LAWLOR, B. A., Kennelly, S., O'Dwyer, S., Cregg, F., Walsh, C., Coen, R. F., Kenny, R. A., Howard, R. J., Murphy, C., Adams, J., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006364 · Cited by 45 · see citing works

Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding

Shackleton, B., Crawford, F., & Bachmeier, C. J. (2016) · Fluids and Barriers of the CNS · doi:10.1186/s12987-016-0038-x · Cited by 45 · see citing works

The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases

Cataldi, M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030004 · Cited by 44 · see citing works

Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Blood–Brain Barrier

Bachmeier, C. J., Beaulieu‐Abdelahad, D., Crawford, F., MULLAN, M. J., & Paris, D. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9866-6 · Cited by 41 · see citing works

Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier

Shackleton, B., Ringland, C., Abdullah, L. I., MULLAN, M. J., Crawford, F., & Bachmeier, C. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01672-z · Cited by 40 · see citing works

Dementia risk with antihypertensive use and blood pressure variability

Tully, P. J., Dartigues, J., Debette, S., Helmer, C., Artéro, S., & Tzourio, C. (2016) · Neurology · doi:10.1212/wnl.0000000000002946 · Cited by 39 · see citing works

Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease

Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 38 · see citing works

Treating Hypertension to Prevent Cognitive Decline and Dementia: Re-Opening the Debate

Iulita, M. F., & Girouard, H. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_98 · Cited by 36 · see citing works

Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo

Lam, M., Mast, N., & Pikuleva, I. A. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.110742 · Cited by 37 · see citing works

Current druggable targets for therapeutic control of Alzheimer's disease

Gupta, G. L., & Samant, N. P. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106549 · Cited by 38 · see citing works

Therapeutic Approaches to Alzheimer’s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection

Taliyan, R., Chandran, S. K., & Kakoty, V. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190716101411 · Cited by 35 · see citing works

A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice

Li, T., Jiao, J., Su, Q., Hölscher, C., Zhang, J., Yan, X., Zhao, H., Cai, H.-Y., & Qi, J. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108042 · Cited by 36 · see citing works

FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer’s Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation

Bao, X.-Q., Li, N., Wang, T., Kong, X., Tai, W., Sun, H., & Zhang, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078033 · Cited by 34 · see citing works

Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1,4-dihydropyridine derivatives

Ruciņš, M., Kaldre, D., Pajuste, K., Fernandes, M. A. S., Vicente, J. A. F., Klimavičiusa, L., Jaschenko, E., Kanepe, I., Shestakova, I., Plotniece, M., et al. (2013) · Comptes Rendus Chimie · doi:10.1016/j.crci.2013.07.003 · Cited by 32 · see citing works

Why calcium channel blockers could be an elite choice in the treatment of Alzheimer’s disease: a comprehensive review of evidences

Ponne, S., Chinnadurai, R. K., & Boopathy, R. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0056 · Cited by 31 · see citing works

Gramine Derivatives Targeting Ca2+ Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases

Lajarín-Cuesta, R., Nanclares, C., Arranz-Tagarro, J.-A., González‐Lafuente, L., Arribas, R. L., de Brito, M. A., Gandı́a, L., & Rı́os, C. D. L. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00478 · Cited by 30 · see citing works

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27 · see citing works

Modulation of L-type calcium channels in Alzheimer’s disease: A potential therapeutic target

Crossley, C. A., Rajani, V., & Yuan, Q. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.049 · Cited by 28 · see citing works

European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow

Meulenbroek, O., O'Dwyer, S., de Jong, D., van Spijker, G. J., Kennelly, S., Cregg, F., Rikkert, M. G. M. O., Abdullah, L. I., Wallin, A., Walsh, C., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011584 · Cited by 27 · see citing works

Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant

Diamantopoulou, E., Baxendale, S., de León, A. D. L. V., Asad, A., Holdsworth, C. J., Abbas, L., Gillet, V. J., Wiggin, G. R., & Whitfield, T. T. (2019) · eLife · doi:10.7554/elife.44889 · Cited by 27 · see citing works

Accelerated DNA methylation age and medication use among African Americans

Kho, M., Wang, Y.-Z., Chaar, D., Zhao, W., Ratliff, S. M., Mosley, T. H., Peyser, P. A., Kardia, S. L. R., & Smith, J. A. (2021) · Aging · doi:10.18632/aging.203115 · Cited by 26 · see citing works

Influence of acute or chronic calcium channel antagonists on the acquisition and consolidation of memory and nicotine-induced cognitive effects in mice

Biała, G., Kruk-Słomka, M., & Jóźwiak, K. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0866-z · Cited by 27 · see citing works

Nitrendipine and Dementia: Forgotten Positive Facts?

Novotný, M., Klímová, B., & Vališ, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00418 · Cited by 27 · see citing works

Effects of Hypertension on Alzheimer’s Disease and Related Disorders

Malone, J. E., Elkasaby, M., & Lerner, A. J. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01221-5 · Cited by 26 · see citing works

Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders

Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 24 · see citing works

Influence of traumatic brain injury on extracellular tau elimination at the blood–brain barrier

Eisenbaum, M., Pearson, A., Gratkowski, A., Mouzon, B., MULLAN, M. J., Crawford, F., Ojo, J. O., & Bachmeier, C. J. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00283-y · Cited by 25 · see citing works

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

Abdullah, L. I., Crawford, F., Tsolaki, M., Börjesson‐Hanson, A., Rikkert, M. G. M. O., Pasquier, F., Wallin, A., Kennelly, S., Ait‐Ghezala, G., Paris, D., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00149 · Cited by 24 · see citing works

Amlodipine treatment of hypertension associates with a decreased dementia risk

Feldman, L., Vinker, S., Efrati, S., Beberashvili, I., Gorelik, O., Wasser, W. G., & Shani, M. (2016) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2016.1174249 · Cited by 23 · see citing works

Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease

Ruthirakuhan, M. T., Herrmann, N., Suridjan, I., Abraham, E. H., Farber, I., & Lanctôt, K. L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258060 · Cited by 22 · see citing works

Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI

Morin, A., Mouzon, B., Ferguson, S., Paris, D., Browning, M., Stewart, W. B., Jr., Mullan, M., & Crawford, F. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01045-x · Cited by 21 · see citing works

A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25–35-impaired mouse cognitive function

Zhang, Z., Chen, R., An, W., Wang, C., Liao, G., Dong, X., Bi, A., Yin, Z., & Luo, L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4133-5 · Cited by 21 · see citing works

Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review

Peters, J., Booth, A., & Peters, R. K. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315582353 · Cited by 20 · see citing works

Learning on Jupiter, learning on the Moon: the dark side of the G-force. Effects of gravity changes on neurovascular unit and modulation of learning and memory

Porte, Y., & Morel, J. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00064 · Cited by 21 · see citing works

Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease

Tapias, V., González-Andrés, P., Fernández-Peña, L., Barbero, A., Núñez, L., & Villalobos, C. (2023) · Antioxidants · doi:10.3390/antiox12061282 · Cited by 20 · see citing works

Novel Multipotent AChEI-CCB Attenuates Hyperhomocysteinemia-Induced Memory Deficits and Neuropathologies in Rats

Xia, Y., Liu, R., Chen, R., Tian, Q., Zeng, K., Hu, J., Liu, X., Wang, Q., Wang, P., Wang, X., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140597 · Cited by 19 · see citing works

Post-Translational Modification of Cav1.2 and its Role in Neurodegenerative Diseases

Li, Y., Yang, H., He, T., Zhang, L., & Liu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775087 · Cited by 19 · see citing works

A novel tacrine-dihydropyridine hybrid (-)SCR1693 induces tau dephosphorylation and inhibits Aβ generation in cells

Wang, X., Xiong, Y., Yang, Y., Tuo, Q., Wang, X., Chen, R., Tian, Q., Zhang, Z.-P., Yan, X., Yang, Z.-Y., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.022 · Cited by 18 · see citing works

GV1001 modulates neuroinflammation and improves memory and behavior through the activation of gonadotropin-releasing hormone receptors in a triple transgenic Alzheimer's disease mouse model.

Park, H., Kwon, H., Lee, K.-Y., Kim, Y. E., Son, J., Choi, N.-Y., Lee, E. J., Han, M.-H., Park, D. W., Kim, S., et al. (2023) · Brain, behavior, and immunity · doi:10.1016/j.bbi.2023.10.021 · Cited by 13 · see citing works

A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI Mice

Jansone, B., Kadish, I., van Groen, T., Beitnere, U., Moore, D. R., Plotniece, A., Pajuste, K., & Klusa, V. Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127686 · Cited by 15 · see citing works

Emerging amyloid and tau targeting treatments for Alzheimer’s disease

Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 15 · see citing works

Repurposing Licensed Drugs for Use Against Alzheimer’s Disease

Norins, L. C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210080 · Cited by 13 · see citing works

Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications

Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C., & Salomone, S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990141 · Cited by 12 · see citing works

A Timeline of Ca2+/cAMP Signalling: From Basic Research to Potential Therapeutics for Dementia

Bergantin, L. B. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220415125447 · Cited by 11 · see citing works

Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems

Loeffler, D. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240212 · Cited by 12 · see citing works

Tackling Alzheimer’s Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles

Rampa, A., Gobbi, S., Belluti, F., & Bisi, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831140745 · Cited by 11 · see citing works

Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data

Sternberg, Z., Podolsky, R., Yu, J., Tian, M., Hojnacki, D., & Schaller, B. J. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.73 · Cited by 10 · see citing works

Current updates on latest basic research of scientific relevance in hypertensive dementia

Mogi, M., Takami, Y., Ihara, M., Yamashita, T., Takeda, S., Shibata, S., Node, K., Kario, K., Prevention of Cognitive Impairment by Hypertension Management (PCIHM) Working Group of the Japanese Society of Hypertension, Mogi, M., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02417-3 · Cited by 11 · see citing works

Synthesis and fluorescence behavior of photoactive polyhydroquinoline derivatives: A combined experimental and DFT study

Phukan, S., Saha, M., Pal, A. K., & Mitra, S. (2013) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2013.02.004 · Cited by 9 · see citing works

Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7

Torres-Rico, M., García-Calvo, V., Gironda-Martínez, A., Pascual-Guerra, J., Garcı́a, A. G., & Maneu, V. (2024) · Cell Calcium · doi:10.1016/j.ceca.2024.102928 · Cited by 7 · see citing works

Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease

Martins, G. L., Ferreira, C. N., Palotás, A., Rocha, N. P., & Reis, H. J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327215245 · Cited by 6 · see citing works

Molecular insights into nilvadipine–hemoglobin interactions: conformational dynamics and binding mechanisms

Khan, M. S., Rehman, M. T., Altwaijry, N. A., Alafaleq, N. O., Aldobiyan, I., Alokail, M. S., Alzahrani, A. A., Arshad, M., & Alajmi, M. F. (2025) · RSC Advances · doi:10.1039/d5ra04162g · Cited by 4 · see citing works

L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model

Wickline, J. L., Smith, S. A., Shin, R., Odfalk, K. F., Sanchez, J., Javors, M. A., Ginsburg, B. C., & Hopp, S. C. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109454 · Cited by 4 · see citing works

Nitrendipine, an antihypertensive alpha calcium channel blocker, is cytotoxic to neuroblastoma cells

Rivera, I., Cauvi, D. M., Arispe, N. J., & Maio, A. D. (2019) · Molecular & Cellular Toxicology · doi:10.1007/s13273-019-0051-7 · Cited by 4 · see citing works

Transcriptome and Animal Model Integration Reveals Inhibition of Calcium Homeostasis-Associated Gene ITPKB Alleviates Amyloid Plaque Deposition

Hu, Y., Zhao, Z., Xu, F., Ren, X., Liu, M., Zheng, Z., & Wang, Q. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02221-7 · Cited by 3 · see citing works

Connections Between Hypertension, Atherosclerosis, Acute Myocardial Infarction, and Risk of Dementia

Stern, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000739 · Cited by 3 · see citing works

Inhibition of Dendritic L-Type Calcium Current by Memantine in Frog Tectum

Baginskas, A., Kuras, A., & Grigaliūnas, A. (2013) · Medicina · doi:10.3390/medicina49090064 · Cited by 2 · see citing works

Navigating the Landscape of Alzheimer's Disease: From Epidemiology to Drug Re-purposing

Rathi, K., Bhole, R. P., Bansode, P., & Motghare, N. (2024) · Advances in Pharmacology and Pharmacy · doi:10.13189/app.2024.120206 · Cited by 2 · see citing works

From comorbidity to continuum: Alzheimer’s disease and epilepsy are connected-now what?

Alves, S. S., Manzine, P. R., dos Santos, F. M., Migliaccio, M. M., Alves, L. D. C., da Silva-Júnior, R. M. P., Becerra-Hernández, L. V., González-Acosta, C. A., Buriticá, E., Cominetti, M. R., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106682 · Cited by 1 · see citing works

Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the

Barrier, B.-B., Ganey, J., Beaulieu‐Abdelahad, D., Ait‐Ghezala, G., Crawford, F., & Mullan, M. J. (2012)

Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier

Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.048 · Cited by 61 · see citing works

Improvement of cerebral blood flow and cognition in transgenic mouse models of Alzheimer's disease by nilvadipine

MULLAN, M. J., Quadros, A., Patel, N. S., Volmar, C., & Paris, D. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.083

Calcium Channel Blockers used as Anti-Hypertension Agents Affect the Toxicity of Aβ Peptides on Neurons

Arispe, N. J., Williams, M. R., Rivera, I., Lin, H., Cauvi, D. M., & Maio, A. D. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2013.11.1721 · Cited by 2 · see citing works

P4–309: Development of cardiovascular β–amyloid lowering drugs as a treatment in Alzheimer‘s disease

Wang, J., Zhao, R., Bartholomew, S. R., Chen, L.-H., Seror, I., Humala, N., Ling, E., Pasinetti, G. M., & Ho, L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.2050